Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A.
Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Palatin is a biopharmaceutical company that is currently in the scale-up stage. The company has significantly expanded its research and development activities, focusing on novel therapeutics for inflammatory and autoimmune conditions. Palatin's emphasis on leveraging the melanocortin system showcases its commitment to innovative treatment approaches.
Palatin has achieved several significant milestones in its history, including successful clinical trial developments, research advancements in the melanocortin system, and strategic partnerships with key players in the pharmaceutical industry. The company has also demonstrated notable revenue growth and market penetration, establishing a strong foothold in the treatment of inflammatory and autoimmune diseases.
Palatin has been involved in several notable case studies highlighting the efficacy of its novel therapeutics in resolving harmful inflammation in patients with inflammatory and autoimmune conditions. These case studies underscore the positive impact of Palatin's treatments on patient outcomes and quality of life, showcasing the company's dedication to addressing unmet medical needs through innovative solutions.
Palatin has had several key events in its history, including the successful launch of VYLEESI® (bremelanotide injection) for ocular conditions, strategic partnerships with leading pharmaceutical companies, and significant funding rounds to support its research and development efforts. The company has also received important industry recognition and awards for its groundbreaking work in leveraging the melanocortin system for the treatment of inflammatory and autoimmune diseases.
-
Active
Health Care
Life Sciences
Cedar Brook Corporate Center 4-B Cedar Brook Drive Cranbury New Jersey 08512 United States...
Jersey
34
Joseph Stanley Hull (Independent Director)
Stephen T. Wills (COO, CFO, Secretary, Treasurer & Executive VP)
John Dodd (Senior Vice President-Preclinical Development)
4.85 M
€1.19
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDCAiDOOS Information Wiki provides comprehensive information about products, companies, and individuals.
-
Health Care
Life Sciences
Cedar Brook Corporate Center 4-B Cedar Brook Drive Cranbury New Jersey 08512 United States...
Jersey
34+
4.85 M
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A.
Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center. Learn More About Us
Book A Meeting To Setup Your VDC